Locations:
Search IconSearch
April 10, 2023/News Updates

U.S. Surgeon General Visits Cleveland Clinic to Speak About Youth Mental Health

Media Downloads

Content is property of Cleveland Clinic and for news media use only.

Newsroom Dr. Mihaljevic and U.S. Surgeon General

U.S. Surgeon General Vice Admiral Vivek H. Murthy, M.D., MBA, visited Cleveland April 5 as part of his multi-city tour focused on youth mental health and community priorities.

While on Cleveland Clinic’s main campus, Dr. Murthy participated in a fireside chat with Cleveland Clinic providers.

The chat was hosted by Cleveland Clinic CEO and President Tom Mihaljevic, M.D., holder of the Morton L. Mandel CEO Chair.

During this unique opportunity, Dr. Murthy discussed mental health challenges facing youth today, the impact on all aspects of a person’s health, and the important role healthcare providers play in mental wellbeing.

You can watch a recording of the fireside chat below.

U.S. Surgeon General Speaks About Youth Mental Health at Cleveland Clinic

Latest from the Newsroom

Beri Ridgeway, M.D.

Cleveland Clinic Appoints Beri Ridgeway, M.D., as President of Cleveland Clinic London

Genediting Therapy Shows Success Against Severe Sickle Cell Disease

Gene Editing Therapy Shows Success Against Severe Sickle Cell Disease

Cleveland Clinic's Main Campus lobby

Mandel Foundation Donates $50 Million to Improve Access to Care at Cleveland Clinic

Blood pressure cuff

Experimental Monthly Injectable Reduces a Key Regulator of Blood Pressure

GLP-1 injection pen with a stethoscope

Tirzepatide Associated with Lower Risk of Heart and Kidney Damage Compared to Dulaglutide in Patients with Type 2 Diabetes and Cardiovascular Disease

Hospital Care At Home

Cleveland Clinic Introduces Hospital Care At Home in Ohio

Image of a scaled and tape measure

What Happens When Patients Stop Taking GLP-1 Drugs? New Cleveland Clinic Study Reveals Real World Insights

Illustration of digital medical records

AI-Driven Chart Review Accurately Identifies Potential Rare Disease Trial Participants in New Study